Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Artiva Biotherapeutics, Inc. Common Stock
ARTVCurrent price
6.97 USD
-0.6 USD (-7.93%)
Last closed
7.66 USD
Company
www.artivabio.com
ISIN
unknown
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
252 608 704 USD
Yield for 12 month
-41.92 %
1Y
3Y
5Y
10Y
15Y
ARTV
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California. Address: 5505 Morehouse Drive, San Diego, CA, United States, 92121
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
21.25 USDP/E ratio
–Dividend Yield
–Current Year
+33 492 000 USD
Last Year
+4 931 000 USD
Current Quarter
–
Last Quarter
–
Current Year
+33 492 000 USD
Last Year
+4 931 000 USD
Current Quarter
–
Last Quarter
–
Key Figures ARTV
1 year
3 years
5 years
10 years
EBITDA
-58 574 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
–
PEG Ratio
–
Return On Equity TTM
-44.21 %
Wall Street Target Price
21.25 USD
Revenue TTM
2 601 000 USD
Book Value
8.28 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-74.60 %
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-2.48 USD
Diluted Eps TTM
-2.48 USD
Most Recent Quarter
III 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics ARTV
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History ARTV
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation ARTV
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
46.50
Price Sales TTM
97.12
Enterprise Value EBITDA
–
Price Book MRQ
1.26
Financials ARTV
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators ARTV
For 52 weeks
9.68 USD
17.31 USD
50 Day MA
12.13 USD
Shares Short Prior Month
935 773
200 Day MA
11.96 USD
Short Ratio
20.47
Shares Short
1 031 283
Short Percent
4.27 %
BeatStart